Enliven Therapeutics Inc. (ELVN NASDAQ) stock market data APIs
$21.7711
-3.24(-14.9%)
as of June 13, 2025
Try our APIs with
free plan!
Enliven Therapeutics Inc. Financial Data Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Prev. Close
21.7711
Open
18.5264
High
23.7214
Low
18.5264
52 wk Range
13.3-30.03
Market Cap
1 075 M
Shares Outstanding
49 069 K
EPS
-0.57
Beta
0.951
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enliven Therapeutics Inc. data using free add-ons & libraries
Get Enliven Therapeutics Inc. Fundamental Data
Enliven Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -109 948 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.5043
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enliven Therapeutics Inc. News
New
Goldman Sachs initiates Enliven Therapeutics stock with Buy rating
Goldman Sachs initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) Monday with a Buy rating and a $37.00 price target, citing positive Phase 1 data for the company’s chronic myeloid leukemia (CM...
Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares
(RTTNews) - Enliven Therapeutics, Inc. (ELVN), a company focused on the discovery and development of small molecule therapeutics, said on Friday that it has commenced an underwritten public offering o...
Enliven Therapeutics (ELVN) Shares Cross Above 200 DMA
In trading on Wednesday, shares of Enliven Therapeutics Inc (Symbol: ELVN) crossed above their 200 day moving average of $22.39, changing hands as high as $22.52 per share. Enliven Therapeutics Inc s...
Enliven price target lowered to $27 from $36 at JonesResearch
JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company’s abstract from the Phase 1 late line chronic m...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
